Aisling Smith

Aisling Smith

Auto-generated profile, based on publicly available information

Aisling Smith

Department of Neonatology, Rotunda Hospital, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
AEAfif El-Khuffash
Afif El-Khuffash
NBNeidín Bussmann
Neidín Bussmann
CBColm R. Breatnach
Colm R. Breatnach
ASAisling Smith
Aisling Smith
ETElizabeth Tully
Elizabeth Tully
PMPatrick J. McNamara
Patrick J. McNamara

27 June 2019 in Echocardiography
Verified
Journal Article
Closed access
PDF file
ASAisling Smith
Aisling Smith
JPJyothsna R. Purna
Jyothsna R. Purna
MCMichael P. Castaldo
Michael P. Castaldo
Daniel Ibarra-RiosDaniel Ibarra-Rios
Daniel Ibarra-Rios
RGRegan E. Giesinger
Regan E. Giesinger
PMPatrick McNamara
Patrick McNamara

9 July 2018 in Children
Verified
Journal Article
Open access
PDF file
AGAisling Garvey
Aisling Garvey
EKElisabeth M.W. Kooi
Elisabeth M.W. Kooi
ASAisling Smith
Aisling Smith
EDEugene Dempsey
Eugene Dempsey
Near-infrared spectroscopy (NIRS) allows for continuous, non-invasive monitoring of end-organ tissue oxygenation. The use of NIRS, cerebral NIRS (cNIRS) in particular, in neonatal care has increased significantly over the last few years. This dynamic monitoring technique provides real-time information on the cerebral and haemodynamic status of the neonate and has the potential to serve as an important adjunct to patient care with some centres routinely utilising cNIRS to aid decision-making at the bedside. cNIRS values may be influenced by many variables, including cardiac, respiratory and metabolic parameters, and therefore it is essential to understand the pathophysiology behind alterations in cNIRS values. Correct interpretation is required to direct appropriate patient-specific interventions. This article aims to assist clinicians in deciphering cNIRS values by providing an overview of potential causes of fluctuations in cNIRS values, illustrated by common clinical scenarios, with particular emphasis on the preterm infant.

15 January 2021 in Children
Verified
Journal Article
Open access
PDF file
ASAisling Smith
Aisling Smith
AEAfif El-Khuffash
Afif El-Khuffash
The identification of an optimal management strategy for the patent ductus arteriosus (PDA) in the context of extreme prematurity remains elusive. Observational studies have reported a persistent association between PDA and neonatal adverse outcomes, but by and large, no clinical trial, to date, has demonstrated that treating a PDA results in a reduction of those morbidities. This discrepancy has led many to assume that the PDA is an innocent bystander in the physiological mechanisms responsible for such complications and a reluctance to actively pursue shunt elimination. It would be remiss to discount the volume of evidence available clearly documenting a strong association between longstanding PDA exposure and negative outcomes. There needs to be a radical change in the design, patient selection and possible outcome assessment in any further trials addressing the PDA. The purpose of this review is to explore the reasons that preclude existing clinical trials from definitively ascribing a causal relationship between PDA patency and adverse outcomes in the context of extreme prematurity, why previous studies have failed to demonstrate significant beneficial effects following PDA treatment and how future research may be conducted to allow us to draw concrete conclusions regarding the potential merits of ductal closure.

3 December 2018 in Maternal Health, Neonatology and Perinatology
Verified
Journal Article
Open access
PDF file
AEAfif El-Khuffash
Afif El-Khuffash
PMPatrick McNamara
Patrick McNamara
CBColm Breatnach
Colm Breatnach
NBNeidin Bussmann
Neidin Bussmann
ASAisling Smith
Aisling Smith
EDEugene Dempsey
Eugene Dempsey
Persistent pulmonary hypertension of the newborn (PPHN) is a relatively common condition which results in a mortality of up to 33%. Up to 40% of infants treated with nitric oxide (iNO) either have a transient response or fail to demonstrate an improvement in oxygenation. Milrinone, a selective phosphodiesterase 3 (PDE3) inhibitor with inotropic and lusitropic properties may have potential benefit in PPHN. This pilot study was developed to assess the impact of milrinone administration on time spent on iNO in infants with PPHN. This is a multicentre, randomized, double-blind, two arm pilot study, with a balanced (1:1) allocation of 20 infants. In this pilot study, we hypothesise that infants ≥34 weeks gestation and ≥ 2000 g with a clinical and echocardiography diagnosis of PPHN, intravenous milrinone used in conjunction with iNO will result in a reduction in the time spent on iNO. In addition, we hypothesise that milrinone treatment will lead to an improvement in myocardial performance and global hemodynamics when compared to iNO alone. We will also compare the rate of adverse events associated with the milrinone, and the pre-discharge outcomes of both groups. The purpose of this pilot study is to assess the feasibility of performing the trial and to obtain preliminary data to calculate a sample size for a definitive multi-centre trial of milrinone therapy in PPHN. Trial registration: www.isrctn.com ; ISRCTN:12949496 ; EudraCT Number:2014–002988-16.

24 November 2016 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
ASA. Smith
A. Smith
EDE. Dunne
E. Dunne
MMM. Mannion
M. Mannion
COC. O’cOnnor
C. O’cOnnor
IKI. Knerr
I. Knerr
ECE. Crushell
E. Crushell